Amphivena Therapeutics

OverviewSuggest Edit

Our mission is to eradicate blood cancers with a breakthrough therapy that harnesses the patient’s own immune system to destroy tumor cells and their precursors. Our aim is to restore the cellular balance needed for proper blood formation, function and circulation, restoring the flow of life to patients that face life threatening illnesses.
TypePrivate
Founded2012
HQSouth San Francisco, CA, US
Websiteamphivena.com

Latest Updates

Employees (est.) (Sept 2021)17
Cybersecurity ratingBMore

Key People/Management at Amphivena Therapeutics

Christian Richard

Christian Richard

Director
Curtis Ruegg

Curtis Ruegg

Chief Executive Officer and President, Director
Vinay Bhaskar

Vinay Bhaskar

Director
Victoria Smith

Victoria Smith

Chief Scientific Officer
Patrick Chun

Patrick Chun

Vice President Clinical Development
Amy Penticoff

Amy Penticoff

Vice President Technical Operations
Show more

Amphivena Therapeutics Office Locations

Amphivena Therapeutics has an office in South San Francisco
South San Francisco, CA, US (HQ)
1828, One, Tower Pl
Show all (1)

Amphivena Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2012

Amphivena Therapeutics total Funding

$127.2 m

Amphivena Therapeutics latest funding size

$62 m

Time since last funding

2 years ago

Amphivena Therapeutics investors

Amphivena Therapeutics's latest funding round in September 2019 was reported to be $62 m. In total, Amphivena Therapeutics has raised $127.2 m
Show all financial metrics

Amphivena Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

81/100

SecurityScorecard logo

Amphivena Therapeutics Online and Social Media Presence

Embed Graph

Amphivena Therapeutics News and Updates

Amphivena Therapeutics to Present at the Jefferies Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 29, 2020 /PRNewswire/ -- Amphivena Therapeutics, a clinical-stage immuno-oncology company focused on developing immunotherapeutics that restore anti-cancer immunity to the patient, today announced that Curtis Ruegg, Ph.D., President and CEO, will present a...

Amphivena Therapeutics lands $62 mln Series C

South San Francisco-based Amphivena Therapeutics Inc, a developer of T cell engager therapeutics for cancer, has raised $62 million in Series C financing. NanoDimension and Qiming Venture Partners USA led the round.

Amphivena Therapeutics Frequently Asked Questions

  • When was Amphivena Therapeutics founded?

    Amphivena Therapeutics was founded in 2012.

  • Who are Amphivena Therapeutics key executives?

    Amphivena Therapeutics's key executives are Christian Richard, Curtis Ruegg and Vinay Bhaskar.

  • How many employees does Amphivena Therapeutics have?

    Amphivena Therapeutics has 17 employees.

  • Who are Amphivena Therapeutics competitors?

    Competitors of Amphivena Therapeutics include Roivant Sciences, AbbVie and Genor Biopharma.

  • Where is Amphivena Therapeutics headquarters?

    Amphivena Therapeutics headquarters is located at 1828, One, Tower Pl, South San Francisco.

  • Where are Amphivena Therapeutics offices?

    Amphivena Therapeutics has an office in South San Francisco.

  • How many offices does Amphivena Therapeutics have?

    Amphivena Therapeutics has 1 office.